Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004

Diagnostic Microbiology and Infectious Disease

Volumn 53, Issue 4, 2005, Pages 265-271

  Unal, Serhat ^a   Garcia Rodriguez, Jose Angel ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Acinetobacter spp.; Meropenem; MYSTIC; Pseudomonas aeruginosa; Susceptibility

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG SENSITIVITY; EUROPE; GEOGRAPHY; HEALTH PROGRAM; HOSPITAL INFECTION; HUMAN; NORTH AMERICA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SOUTH AMERICA; TIME SERIES ANALYSIS;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ASIA; AUSTRALIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; INPATIENTS; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; POPULATION SURVEILLANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SOUTH AMERICA; THIENAMYCINS;

EID: 29144520663     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.10.002     Document Type: Article

References (49)

1. S. Aksaray, B. DokuzoGuz, E. Guvener, M. Yucesoy, N. Yulug, S. Kocagoz, S. Unal, S. Cetin, S. Calangu, M. Gunaydin, H. Leblebicioglu, S. Esen, B. Bayar, A. Willke, D. Findik, I. Tuncer, B. Baysal, F. Gunseren, and L. Mamikoglu Surveillance of antimicrobial resistance among gram-negative isolates from intensive care units in eight hospitals in Turkey J. Antimicrob. Chemother. 45 2000 695 699
2. E. Bergogne-Berezin Current guidelines for the treatment and prevention of nosocomial infections Drugs 58 1999 51 67
3. E. Bergogne-Berezin The increasing role of Acinetobacter species as nosocomial pathogens Curr. Infect. Dis. Rep. 3 2001 440 444
4. S. Bratu, J. Quale, S. Cebular, R. Heddurshetti, and D. Landman Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: Molecular epidemiology and in vitro activity of polymyxin B Eur. J. Clin. Microbiol. Infect. Dis. 24 2005 196 201
5. J. Carlet, A. Ben Ali, and A. Chalfine Epidemiology and control of antibiotic resistance in the intensive care unit Curr. Opin. Infect. Dis. 17 2004 309 316
6. M. Cizman, B. Beovic, V. Krcmery, B. Barsic, E. Tamm, E. Ludwig, M. Pelemis, K. Karovski, P. Grzesiowski, D. Gardovska, A. Volokha, E. Keuleyan, L. Stratchounski, C. Dumitru, L.P. Titov, V. Usonis, and P. Dvorak Antibiotic policies in Central Eastern Europe Int. J. Antimicrob. Agents 24 2004 199 204
7. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing (Document M100-S15) 2005 CLSI Villanova (PA)
8. G.L. Drusano, H. Lode, and J.R. Edwards Meropenem: Clinical response in relation to in vitro susceptibility Clin. Microbiol. Infect. 6 2000 185 194
9. R. Finch Antibiotic resistance-from pathogen to disease surveillance Clin. Microbiol. Infect. 8 2002 317 320
10. A.C. Fluit, J. Verhoef, and F.J. Schmitz Antimicrobial resistance in European isolates of Pseudomonas aeruginosa Eur. J. Clin. Microbiol. Infect. Dis. 19 2000 370 374
11. A.C. Gales, R.N. Jones, K.R. Forward, J. Linares, H.S. Sader, and J. Verhoef Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999) Clin. Infect. Dis. 32 2001 104 113
12. J.A. Garcia-Rodriguez, R.N. Jones the MYSTIC Programme Study Group Antimicrobial resistance in gram-negative isolates from European intensive care units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme J. Chemother. 14 2002 25 32
13. H. Goossens MYSTIC Program: Summary of European data from 1997 to 2000 Diagn. Microbiol. Infect. Dis. 41 2001 183 189
14. H. Hanberger, J.A. Garcia-Rodriguez, M. Gobernado, H. Goossens, L.E. Nilsson, and M.J. Struelens Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups JAMA 281 1999 67 71
15. C.J. Henwood, D.M. Livermore, D. James, and M. Warner Antimicrobial susceptibility of Pseudomonas aeruginosa: Results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test J. Antimicrob. Chemother. 47 2001 789 799
16. R.N. Jones Resistance patterns among nosocomial pathogens: Trends over the past few years Chest 119 2001 397S 404S
17. R.N. Jones, L. Deshpande, T.R. Fritsche, and H.S. Sader Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003) Diagn. Microbiol. Infect. Dis. 49 2004 211 216
18. R.N. Jones, J.T. Kirby, M.L. Beach, D.J. Biedenbach, and M.A. Pfaller Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: Summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000) Diagn. Microbiol. Infect. Dis. 43 2002 239 243
19. R.N. Jones, and R. Masterton Determining the value of antimicrobial surveillance programs Diagn. Microbiol. Infect. Dis. 41 2001 171 175
20. R.N. Jones, and M.A. Pfaller Bacterial resistance: A worldwide problem Diagn. Microbiol. Infect. Dis. 31 1998 379 388
21. C.R. Kiffer, C. Mendes, J.L. Kuti, and D.P. Nicolau Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: The OPTAMA Program, South America 2002 Diagn. Microbiol. Infect. Dis. 49 2004 109 116
22. M. Kollef Appropriate empirical antibacterial therapy for nosocomial infections: Getting it right the first time Drugs 63 2003 2157 2168
23. J.L. Kuti, and D.P. Nicolau Making the most of surveillance studies: Summary of the OPTAMA program Diagn. Microbiol. Infect. Dis. 2005 (submitted for publication)
24. J.L. Kuti, C.H. Nightingale, and D.P. Nicolau Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram: Data collected in North America in 2002 Antimicrob. Agents Chemother. 48 2004 2464 2470
25. D. Landman, J.M. Quale, D. Mayorga, A. Adedeji, K. Vangala, J. Ravishankar, C. Flores, and S. Brooks Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned Arch. Intern. Med. 162 2002 1515 1520
26. X.Z. Li, L. Zhang, and K. Poole Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa J. Antimicrob. Chemother. 45 2000 433 436
27. D.M. Livermore Of Pseudomonas, porins, pumps and carbapenems J. Antimicrob. Chemother. 47 2001 247 250
28. D.M. Livermore Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34 2002 634 640
29. R.G. Masterton Ciprofloxacin resistance-'early warning' signs from the MYSTIC Surveillance Programme? J. Antimicrob. Chemother. 2002 218 220
30. R. Masterton, G. Drusano, D.L. Paterson, and G. Park Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges J. Hosp. Infect. 55 Suppl 1 2003 1 12
31. R.G. Masterton, J.L. Kuti, P.J. Turner, and D.P. Nicolau The OPTAMA programme: Utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe J. Antimicrob. Chemother. 55 2005 71 77
32. H.M. Mattoes, J.L. Kuti, G.L. Drusano, and D.P. Nicolau Optimizing antimicrobial pharmacodynamics: Dosage strategies for meropenem Clin. Ther. 26 2004 1187 1198
33. C. Mendes, and P.J. Turner Unit differences in pathogen occurrence arising from the MYSTIC Program European database (1997-2000) Diagn. Microbiol. Infect. Dis. 41 2001 191 196
34. A.H. Mutnick, P.R. Rhomberg, H.S. Sader, and R.N. Jones Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001) J. Antimicrob. Chemother. 53 2004 290 296
35. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial test for bacteria that grow aerobically (Document M7-A6) 2003 NCCLS Wayne (PA)
36. M.M. Neuhauser, R.A. Weinstein, R. Rydman, L.H. Danziger, G. Karam, and J.P. Quinn Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use JAMA 289 2003 885 888
37. M.S. Niederman Appropriate use of antimicrobial agents: Challenges and strategies for improvement Crit. Care Med. 31 2003 608 616
38. M.A. Pfaller, R.N. Jones for the MYSTIC Study Group (Americas) MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections J Antimicrob Chemother 46 Suppl T2 2000 25 37
39. M.A. Pfaller, R.N. Jones, D.J. Biedenbach MYSTIC Program Study Group Antimicrobial resistance trends in medical centers using carbapenems: Report of 1999 and 2000 results from the MYSTIC Program (USA) Diagn. Microbiol. Infect. Dis. 41 2001 177 182
40. P.R. Rhomberg, R.N. Jones, H.S. Sader, and T.R. Fritsche Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003) Diagn. Microbiol. Infect. Dis. 49 2004 273 281
41. C.H. Rodriguez, J. Juarez, C. de Mier, L. Pugliese, G. Blanco, C. Vay, and A. Famiglietti Bacterial resistance to antibiotics in gram-negative rods isolated from intensive care units. Comparative analysis between two periods (1998 and 2001) Medicina (B Aires) 63 2003 21 27
42. H.S. Sader, M. Castanheira, R.E. Mendes, M. Toleman, T.R. Walsh, and R.N. Jones Dissemination and diversity of metallo-β-lactamases in Latin America: Report from the SENTRY Antimicrobial Surveillance Program Int. J. Antimicrob. Agents 25 2005 57 61
43. VIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States Antimicrob. Agents Chemother. 48 2004 329 332
44. C. Tuchilus, A. Poiata, D. Bosnea, I. Badicut, and D. Buiuc Resistance pattern of extended-spectrum beta-lactamase producing Enterobacteriaceae isolates Roum. Arch. Microbiol. Immunol. 61 2002 285 291
45. P.J. Turner MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview J. Antimicrob. Chemother. 46 Suppl T2 2000 9 23
46. P.J. Turner Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalised in European medical centres: 6-year report of the MYSTIC surveillance study (1997-2002) Diagn. Microbiol. Infect. Dis. 51 2005 281 289
47. P.J. Turner, J.M. Greenhalgh, J.R. Edwards, and J. McKellar The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme Int. J. Antimicrob. Agents 13 1999 117 125
48. S. Unal, R. Masterton, and H. Goossens Bacteraemia in Europe-antimicrobial susceptibility data from the MYSTIC surveillance programme Int. J. Antimicrob. Agents 23 2004 155 163
49. M.V. Villegas, and J.P. Quinn An update on antibiotic-resistant gram-negative bacteria Infect. Med. 21 2004 595 599